Evidence map›Paper›PMID 34959643›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations.

Philippe-Henri Secretan, Olivier Thirion, Hassane Sadou Yayé, Thibaud Damy, Alain Astier, Muriel Paul, Bernard Do

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Special Issue "Recent Advances in Oral Drug Delivery Development".Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Philippe-Henri SecretanMatériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.ORCID 0000-0002-5838-3695
Olivier ThirionDepartment of Pharmacy, Hôpitaux Universitaires Henri Mondor, AP-HP, 94000 Créteil, France.ORCID 0000-0001-9740-3380
Hassane Sadou YayéDepartment of Pharmacy, Hôpitaux Universitaires Pitié-Salpêtrière, AP-HP, 75013 Paris, France.
Thibaud DamyDépartement de Cardiologie et des Maladies Vasculaires, Hôpitaux Universitaires Henri Mondor, AP-HP, 94000 Créteil, France.
Alain AstierDepartment of Pharmacy, Hôpitaux Universitaires Henri Mondor, AP-HP, 94000 Créteil, France.
Muriel PaulDepartment of Pharmacy, Hôpitaux Universitaires Henri Mondor, AP-HP, 94000 Créteil, France.
Bernard DoMatériaux et Santé, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of its antioxidant, antimutagenic, and anti-infectious properties, epigallocatechin gallate (EGCG) is the most interesting compound among the green tea catechins polyphenols. However, its health effects are inconclusive due to its very low bioavailability, largely due to a particular instability that does not allow EGCG to reach the potency required for clinical developments. Over the last decade, many efforts have been made to improve the stability and bioavailability of EGCG using complex delivery systems such as nanotechnology, but these efforts have not been successful and easy to translate to industrial use. To meet the needs of a large-scale clinical trial requiring EGCG in a concentrated solution to anticipate swallowing impairments, we developed an EGCG-based aqueous solution in the simplest way while trying to circumvent EGCG instability. The solution was thoroughly characterized to sort out the unexpected stability outcome by combining experimental (HPLC-UV-mass spectrometry and infrared spectroscopy) and computational (density functional theory) studies. Against all odds, the EGCG-sucrose complex under certain conditions may have prevented EGCG from degradation in aqueous media. Indeed, in agreement with the ICH guidelines, the formulated solution was shown to be stable up to at least 24 months under 2-8 °C and at ambient temperature. Furthermore, considerable improvement in bioavailability in rats, against EGCG powder formulated in hard-gel capsules, was shown after gavage. Thus, the proposed formulation may provide an easily implementable platform to administer EGCG in the context of clinical development.

Indexed as

complexdensity functional theoryepigallocatechin gallateformulationmass spectrometryoral solutionstability

Identifiers

PMID34959643
PMCPMC8706847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.